LEXICON PHARMACEUTICALS, INC. Revenue from Contract with Customer, Excluding Assessed Tax
LEXICON PHARMACEUTICALS, INC. (LXRX) reported Revenue from Contract with Customer, Excluding Assessed Tax of $1.26 million for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-14.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2025-05-14
- LEXICON PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-03-31 was $1.26M, a 15.46% increase year-over-year.
- LEXICON PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-12-31 was $1.55M, a 130.65% increase year-over-year.
- LEXICON PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-09-30 was $1.74M, a 1076.35% increase year-over-year.
- LEXICON PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-06-30 was $1.62M, a 455.67% increase year-over-year.
- LEXICON PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $6.00M, a 440.63% increase from fiscal 2023.
- LEXICON PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $1.11M.
- LEXICON PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $0.00.
- LEXICON PHARMACEUTICALS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2025-03-31 | $1.26M 10-Q · filed 2025-05-14 | $2.81M derived: sum of 2 quarters · filed 2025-05-14 | $4.55M derived: sum of 3 quarters · filed 2025-05-14 | $6.17M derived: sum of 4 quarters · filed 2025-05-14 |
| 2024-12-31 | $1.55M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $3.29M derived: sum of 2 quarters · filed 2025-03-07 | $4.91M derived: sum of 3 quarters · filed 2025-03-07 | $6.00M 10-K · filed 2025-03-07 |
| 2024-09-30 | $1.74M 10-Q · filed 2024-11-13 | $3.36M derived: sum of 2 quarters · filed 2024-11-13 | $4.45M 10-Q · filed 2024-11-13 | $5.12M derived: sum of 4 quarters · filed 2025-05-14 |
| 2024-06-30 | $1.62M 10-Q · filed 2024-08-02 | $2.71M 10-Q · filed 2024-08-02 | $3.38M derived: sum of 3 quarters · filed 2025-05-14 | $3.53M derived: sum of 4 quarters · filed 2025-05-14 |
| 2024-03-31 | $1.09M 10-Q · filed 2025-05-14 | $1.76M derived: sum of 2 quarters · filed 2025-05-14 | $1.91M derived: sum of 3 quarters · filed 2025-05-14 | $2.20M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $672.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $820.00K derived: sum of 2 quarters · filed 2025-03-07 | $1.11M derived: sum of 3 quarters · filed 2025-03-07 | $1.11M 10-K · filed 2025-03-07 |
| 2023-09-30 | $148.00K 10-Q · filed 2024-11-13 | $439.00K derived: sum of 2 quarters · filed 2024-11-13 | $438.00K 10-Q · filed 2024-11-13 | $439.00K derived: sum of 4 quarters · filed 2025-03-07 |
| 2023-06-30 | $291.00K 10-Q · filed 2024-08-02 | $291.00K 10-Q · filed 2024-08-02 | $291.00K derived: sum of 3 quarters · filed 2025-03-07 | $291.00K derived: sum of 4 quarters · filed 2025-03-07 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-02 | $0.00 derived: sum of 2 quarters · filed 2025-03-07 | $0.00 derived: sum of 3 quarters · filed 2025-03-07 | $0.00 derived: sum of 4 quarters · filed 2025-03-07 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $0.00 derived: sum of 2 quarters · filed 2025-03-07 | $0.00 derived: sum of 3 quarters · filed 2025-03-07 | $0.00 10-K · filed 2025-03-07 |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-08 | $0.00 derived: sum of 2 quarters · filed 2023-11-08 | $0.00 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-04 | $0.00 10-Q · filed 2023-08-04 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $0.00 derived: sum of 2 quarters · filed 2024-03-25 | $0.00 derived: sum of 3 quarters · filed 2024-03-25 | $0.00 10-K · filed 2024-03-25 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-09 | $0.00 derived: sum of 2 quarters · filed 2021-11-09 | $0.00 10-Q · filed 2021-11-09 | $23.37M derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-06 | $0.00 10-Q · filed 2021-08-06 | $23.37M derived: sum of 3 quarters · filed 2023-03-03 | $23.37M derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-06 | $23.37M derived: sum of 2 quarters · filed 2023-03-03 | $23.37M derived: sum of 3 quarters · filed 2023-03-03 | $23.40M derived: sum of 4 quarters · filed 2023-03-03 |
| 2020-12-31 | $23.37M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $23.37M derived: sum of 2 quarters · filed 2023-03-03 | $23.40M derived: sum of 3 quarters · filed 2023-03-03 | $23.40M 10-K · filed 2023-03-03 |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-09 | $25.00K derived: sum of 2 quarters · filed 2021-11-09 | $33.00K 10-Q · filed 2021-11-09 | -$256.85M derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-06-30 | $25.00K 10-Q · filed 2021-08-06 | $33.00K 10-Q · filed 2021-08-06 | -$256.85M derived: sum of 3 quarters · filed 2022-03-10 | $29.07M derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-03-31 | $8.00K 10-Q · filed 2021-05-06 | -$256.87M derived: sum of 2 quarters · filed 2022-03-10 | $29.04M derived: sum of 3 quarters · filed 2022-03-10 | $29.90M derived: sum of 4 quarters · filed 2022-03-10 |
| 2019-12-31 | -$256.88M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $29.03M derived: sum of 2 quarters · filed 2022-03-10 | $29.89M derived: sum of 3 quarters · filed 2022-03-10 | $32.33M 10-K · filed 2022-03-10 |
| 2019-09-30 | $285.91M 10-Q · filed 2020-10-30 | $286.77M derived: sum of 2 quarters · filed 2020-10-30 | $289.21M 10-Q · filed 2020-10-30 | $289.00M derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-06-30 | $860.00K 10-Q · filed 2020-07-29 | $3.30M 10-Q · filed 2020-07-29 | $3.09M derived: sum of 3 quarters · filed 2021-03-12 | $3.65M derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-03-31 | $2.44M 10-Q · filed 2020-04-27 | $2.23M derived: sum of 2 quarters · filed 2021-03-12 | $2.79M derived: sum of 3 quarters · filed 2021-03-12 | $9.19M derived: sum of 4 quarters · filed 2021-03-12 |
| 2018-12-31 | -$209.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $347.00K derived: sum of 2 quarters · filed 2021-03-12 | $6.75M derived: sum of 3 quarters · filed 2021-03-12 | $26.58M 10-K · filed 2021-03-12 |
| 2018-09-30 | $556.00K 10-Q · filed 2019-11-07 | $6.96M derived: sum of 2 quarters · filed 2019-11-07 | $26.79M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $6.40M 10-Q · filed 2019-08-01 | $26.24M 10-Q · filed 2019-08-01 | ||
| 2018-03-31 | $19.83M 10-Q · filed 2019-05-01 | |||
| 2017-12-31 | $15.89M 10-K · filed 2020-03-12 | |||
| 2016-12-31 | $0.00 10-K · filed 2019-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |